Entities / Company
Prothena (Ireland).
company in Dublin, Ireland
- Reports this week
- 0
- Active events
- 0
- Connections
- 26
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
The FDA granted Fast Track designation to PRX012, marking a collaboration between Prothena (Ireland) and Roche for prasinezumab aimed at Parkinson's disease.Some support1 report
-
Prothena announced advancements with Roche regarding prasinezumab, alongside potential milestone payments from Novo Nordisk and Bristol Myers Squibb.Some support2 reports
-
Bridgewater Bancshares is the holding company for Bridgewater Bank, which offers banking products in the U.S., while Prothena develops therapies there.Well supported4 reports
-
Prothena participated in a conference in August 2025, and Mark Johnson works in Investor Relations for the company.Some support3 reports
-
Prothena (Ireland) operates within the biomedical and genetics sector and underperformed the S&P 500 this year.Some support1 report
-
Novo Nordisk acquired Coramitug from Prothena in July 2021, and is now advancing the drug into Phase 3 development for ATTR amyloidosis with cardiomyopathy.Some support1 report
-
Prothena is testing its drug PRX012 in early symptomatic Alzheimer's Disease patients.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Prothena (Ireland) this week
News at the entities that move Prothena (Ireland) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Prothena (Ireland)
-
Novo Nordisk StructuralBridgeBio and Novo Nordisk have both made filings under the KXCO Ontology.Moves Prothena (Ireland)
Connections
The 3 strongest of 26, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Novo Nordisk Structural
Novo Nordisk acquired an asset from Prothena and maintains an ongoing operational partnership tied to milestone payments.
-
FDA Structural
FDA formally regulates and grants designations to products developed by Prothena (Ireland).
-
Mark Johnson Structural
Mark Johnson is employed by Prothena (Ireland) in Investor Relations.
History
Events by the month they beganJune 2026
7 events- The FDA granted Fast Track designation to PRX012, marking a collaboration between Prothena (Ireland) and Roche for prasinezumab aimed at Parkinson's disease.
- Prothena announced advancements with Roche regarding prasinezumab, alongside potential milestone payments from Novo Nordisk and Bristol Myers Squibb.
- Bridgewater Bancshares is the holding company for Bridgewater Bank, which offers banking products in the U.S., while Prothena develops therapies there.
- Prothena participated in a conference in August 2025, and Mark Johnson works in Investor Relations for the company.
- Prothena (Ireland) operates within the biomedical and genetics sector and underperformed the S&P 500 this year.
- Novo Nordisk acquired Coramitug from Prothena in July 2021, and is now advancing the drug into Phase 3 development for ATTR amyloidosis with cardiomyopathy.
- Prothena is testing its drug PRX012 in early symptomatic Alzheimer's Disease patients.